Abstract

The present invention relates to an implantable medical device comprising a layer consisting of or comprising zirconia, and to a method for the preparation thereof.

IPC Classes  ?

• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
• A61C 13/00 - Dental prostheses; Making same
• C04B 35/48 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zirconium or hafnium oxides or zirconates or hafnates

Abstract

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

The electronic circuit performs binary computation operations and comprises word, bit and source lines, and memory cells organized in rows and columns. The electronic circuit performs binary computation operations and comprises word, bit and source lines, and memory cells organized in rows and columns. Each cell includes one pair of memristors and one pair of switches, each memristor being connected to a switch and linked to the same source line during each computation operation, each pair of memristors storing a binary value; the switches being linked to a word line and to a pair of complementary bit lines. The electronic circuit performs binary computation operations and comprises word, bit and source lines, and memory cells organized in rows and columns. Each cell includes one pair of memristors and one pair of switches, each memristor being connected to a switch and linked to the same source line during each computation operation, each pair of memristors storing a binary value; the switches being linked to a word line and to a pair of complementary bit lines. The circuit comprises a reading module including: a logic unit for each column, each comprising an input terminal connected to a source line to receive a column value, the logic unit toggling between values, depending on a comparison of the column value with a toggle threshold value; a modification unit for modifying, for at least one logic unit and depending on the computation operation, a difference between the column and threshold values.

IPC Classes  ?

• G11C 13/00 - Digital stores characterised by the use of storage elements not covered by groups , , or
• G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using elements simulating biological cells, e.g. neuron

Abstract

A pressure-measuring device including an optical fibre with a thinned portion, a laser, called the heating laser, arranged to emit an optical wave, called the heating wave, into the thinned portion, a measuring means including a sensor that is arranged to measure a backscattered optical wave that is generated by an optical wave, called the interrogation wave, and that originates in the thinned portion of the optical fibre, and a processing unit arranged and/or programmed to measure a pressure of a fluid, preferably a gas, encircling the thinned portion, on the basis of the measurement of the backscattered wave.

IPC Classes  ?

• G01L 11/02 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by means not provided for in group or by optical means
• G01L 21/00 - Vacuum gauges

Abstract

A use of an acceptor- less alcohol dehydrogenation catalyst for an electrocatalytic oxidation of an alcohol with an amine, to an imine by electrocatalytic synthesis under electrochemical conditions.

IPC Classes  ?

• C25B 1/02 - Hydrogen or oxygen
• C25B 1/23 - Carbon monoxide or syngas
• C25B 1/50 - Processes
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/23 - Oxidation
• C25B 3/29 - Coupling reactions

Abstract

The present invention relates to novel photosensitive diazirine-conjugated phospholipids, and their use in delivering and releasing an active ingredient in a controlled manner, as well as photosensitive liposomes and controlled delivery systems comprising one or more photosensitive diazirine-conjugated phospholipids. The invention also relates to compositions and kits comprising said photosensitive liposomes, for use in various fields, such as for example in therapy, diagnosis, cosmetics, etc...

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/127 - Liposomes

Abstract

The present invention relates to a method for the synthesis of a solid mixed oxide containing oxides of nickel, magnesium and aluminium and optionally further containing an activator. Characteristically, an ionic solution A containing Ni2+, Mg2+and Al3+233 in a solvent selected from water, organic solvents and mixtures thereof, in particular alcohols and more particularly methanol, and further containing a surfactant, until a suspension is obtained, the solid particles thus obtained are separated and calcined at a temperature equal to or greater than 400°C in particular equal to 550°C.

IPC Classes  ?

• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 23/755 - Nickel
• B01J 23/889 - Manganese, technetium or rhenium
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/00 - Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
• B01J 37/03 - Precipitation; Co-precipitation
• B01J 37/06 - Washing
• B01J 37/08 - Heat treatment

Abstract

The present invention relates to novel peptides (cPEPs & altPEPs), to a method for the preparation thereof, and to the use thereof for modulating the accumulation of specific proteins.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention generally relates to the reuse, reprocessing or recycling of silicone polymers. More precisely, the process of the present invention relates to a method for preparing organopolysiloxanes OR by a depolymerization reaction of at least one silicone S in the presence of an acid catalyst and at least one chain blocker Bc having at least one siloxane function. These organopolysiloxanes OR can subsequently be used in polymerization reactions or directly in various formulations.

IPC Classes  ?

• C08J 11/22 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds
• C08G 77/38 - Polysiloxanes modified by chemical after-treatment
• C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

Systems and methods for managing an execution of an action strategy by an autonomous system are disclosed. The action strategy comprises a series of actions to be performed by the autonomous system to accomplish a corresponding active objective. The method comprises identifying, by a processor of the autonomous system, an active objective to be accomplished by the autonomous system, the active objective describing a hierarchy of actions to be performed to accomplish the corresponding active objective. The method comprises generating, by the processor, an action strategy from the hierarchy of actions of the active objective, the actions of the action strategy corresponding to the actions of the hierarchy of actions of the active objective and executing the action strategy. Upon completion of an execution of an action, the processor provides data comprising information relating to a state of completion of the action strategy.

IPC Classes  ?

• G06F 9/48 - Program initiating; Program switching, e.g. by interrupt

Abstract

Systems, devices, and methods for measuring the dynamic properties of metamaterials at the microscale are provided. For example, laser-induced resonant acoustic spectroscopy (LIRAS) can be used as a non-destructive and/or non-contact optical framework within a material of interest to measure photoacoustic excitation of elastic waves. The system can include a pulsed-laser-based mechanical characterization technique that emits lasers at the sample of interest from various directions to demonstrate a high-throughput non-contact framework that employs MHz-wave propagation signatures to create a vibrational response. The vibrational response of the sample of interest can be used to extract dynamic mechanical properties thereof, such as omnidirectional elastic information, damping properties, and defect quantification. In some embodiments, the LIRAS technique can be employed in a characterization module within an additive manufacturing system to measure parameters of printed parts.

IPC Classes  ?

• G01N 29/24 - Probes
• B22F 12/90 - Means for process control, e.g. cameras or sensors
• B33Y 50/00 - Data acquisition or data processing for additive manufacturing
• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

The present invention relates to new peptides (cPEPs), a method for their preparation, and their use for modulating the accumulation of specific proteins.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

2 2xy2xy2xy22xyy, without the plastic material, that is suitable for degrading another plastic material.

IPC Classes  ?

• B09B 3/50 - Destroying solid waste or transforming solid waste into something useful or harmless involving radiation, e.g. electro-magnetic waves
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 23/02 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the alkali- or alkaline earth metals or beryllium
• B01J 23/40 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of noble metals of the platinum group metals
• B01J 23/50 - Silver
• B01J 23/70 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper
• B01J 35/39 - Photocatalytic properties
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B09B 101/75 - Plastic waste

Abstract

The invention relates to a process for manufacturing a part made of a composite material having a ceramic matrix, the process involving: - infiltrating a pre-densified fibrous structure comprising a powder composition with a molten infiltration composition comprising silicon to form a ceramic matrix in a residual porosity of the pre-densified fibrous structure, the pre-densified fibrous structure comprising a pre-densification matrix comprising silicon carbide, and the powder composition comprising core-shell particles (1) having a silicon carbide core (3) and a shell having at least one layer (5; 51; 52) of boron-doped carbon containing boron at an atomic proportion of 5% to 20%.

IPC Classes  ?

• C04B 35/577 - Composites
• C04B 35/565 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides based on silicon carbide
• C04B 35/573 - Fine ceramics obtained by reaction sintering
• C04B 35/628 - Coating the powders
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
• C04B 35/63 - Preparing or treating the powders individually or as batches using additives specially adapted for forming the products

Abstract

The invention relates to a pipette tip (1, 1') comprising at least one wall portion (2, 2') having a conical shape that is rotationally symmetrical about axis (R), characterized in that said wall portion (2, 2') comprises at least one first wall (20, 20') continuing on a periphery of at least one portion of an inner surface, said first wall projecting from a base (200, 200') in contact with said inner surface to a vertex (201, 201') at an angle of between 40° and 140° with respect to said wall portion (2, 2').

IPC Classes  ?

• B01L 3/02 - Burettes; Pipettes

Abstract

The present invention relates to the combination of a nucleic acid encoding a short isoform of rod- derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a mutated form of the subunit 1 of G-protein- gated inwardly rectifying potassium channel (GIRK1) (GIRK1 F137S) or a mutated form of the subunit 4 of G-protein-gated inwardly rectifying potassium channel (GIRK4) (GIRK4 S143T), the three nucleic acids being expressed through one, two or three viral vectors, and said vectors may be within a single pharmaceutical composition or within several different pharmaceutical compositions (two or three). It also deals with the treatment of a retinal degenerative disease, in particular retinitis pigmentosa, with said viral vectors or pharmaceutical compositions.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least one nanoparticle having a mean hydrodynamic diameter below 10 nm and comprising:. a biocompatible matrix, such as polyorganosiloxane,. at least one chelating agent covalently bonded to said biocompatible matrix,. at least one element having a Z of at least 40, chelated to at least a part of the chelating agents, b) injecting an effective amount of said pharmaceutical to said subject, and, c) acquiring an imaging scan of an anatomical structure of said subject in need thereof, by Spectral Photon Counting Computed Tomography (SPCCT) scanning.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 49/04 - X-ray contrast preparations
• A61K 49/08 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by the carrier
• A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents

Abstract

Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. Here, the inventors studied the effects of intra-articular anti-GD3 monoclonal antibody injection. The present invention relates to a method for treating osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a GD3 inhibitor.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). They performed western blot analysis and confirmed the presence of O-GlcNAc in the blood of the horses and showed that, that the O-GlcNAc levels in septic horses tended to decrease between admission and the first day (D1) after admission. This decrease became significant from the second day (D2) of hospitalization. Accordingly, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

nrr , nii Qrr , Qii i ) and normalized three-dimensional magnetization vector (I) are accurately obtained.

IPC Classes  ?

• G01N 21/21 - Polarisation-affecting properties

Abstract

in vitroin vitro, the present inventors have shown that a combined therapy using HA15, a benzene sulfonamide thiazole compound, and an anticancer treatment such as an immunotherapeutic agent, a chemotherapeutic agent or targeted therapies significantly improves the survival rate and strongly reduces tumor growth as compared to monotherapies comprising either a benzene sulfonamide thiazole compound or an anticancer agent alone.

IPC Classes  ?

• A61K 31/18 - Sulfonamides
• A61K 31/426 - 1,3-Thiazoles
• A61P 35/00 - Antineoplastic agents

Abstract

Methods of and systems for knowledge-based reasoning to establish a list of active objectives by an autonomous system. The method comprises accessing a list of active objectives; accessing a first database populated with static environment properties, the static environment properties defining properties of entities, the entities defining an environment in which the autonomous system is configured to operate; accessing a second database populated with dynamic environment properties comprising third computer-readable instructions generated by the autonomous system based on events having been observed by the autonomous system. Upon observing a new event, a new dynamic environment property is generated based on the new event and coherence checking is executed to assess whether the new dynamic environment property conflicts with at least one of the static environment properties, and, if so, the new dynamic environment property being identified as incoherent.

IPC Classes  ?

• G06N 5/025 - Extracting rules from data

Abstract

The invention relates to variants of a DNA polymerase of the polX family capable of synthesizing a nucleic acid molecule without a template strand, or of a functional fragment of such a polymerase, comprising at least one mutation of a residue in at least one specific position, and to uses of said variants, in particular for the synthesis of nucleic acid molecules comprising 3′-OH modified nucleotides.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to the field of oncology. laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking: to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07C 205/59 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• C07D 207/22 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 487/04 - Ortho-condensed systems
• C12Q 1/6841 - In situ hybridisation

Abstract

The present invention relates to a high-pressure method for preparing a metal monolith either as dense or as highly porous form, by rapid inductive heating hot pressing equipment. The method of the invention allows to obtain a metal monolith from metal powder without binder or any other additives

IPC Classes  ?

• B22F 3/00 - Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor
• B22F 3/11 - Making porous workpieces or articles
• B22F 3/14 - Both compacting and sintering simultaneously
• B22F 1/06 - Metallic powder characterised by the shape of the particles
• B22F 1/065 - Spherical particles
• B30B 15/02 - Dies; Inserts therefor or mountings thereof; Moulds
• B30B 15/34 - Heating or cooling presses or parts thereof
• C22C 1/05 - Mixtures of metal powder with non-metallic powder
• C22C 47/14 - Making alloys containing metallic or non-metallic fibres or filaments by powder metallurgy, i.e. by processing mixtures of metal powder and fibres or filaments
• C22C 49/02 - Alloys containing metallic or non-metallic fibres or filaments characterised by the matrix material
• C22C 49/14 - Alloys containing metallic or non-metallic fibres or filaments characterised by the fibres or filaments

Abstract

48481436141414142214141414141414144)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.

IPC Classes  ?

• C07D 215/40 - Nitrogen atoms attached in position 8
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
• C07D 237/30 - Phthalazines
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine

Abstract

The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.

IPC Classes  ?

• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 35/761 - Adenovirus
• A61K 35/763 - Herpes virus
• A61K 38/44 - Oxidoreductases (1)

Abstract

A microstructured substrate comprising a main body and a plurality of elongated elementary microstructures extending from the main body, wherein the microstructured substrate comprises a plurality of nanowires positioned on at least one area of the surface of the main body and on the surface of the elementary microstructures that extend from the main body over said area.

IPC Classes  ?

• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/28 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features arranged or disposed on a current collector; Layers or phases between electrodes and current collectors, e.g. adhesives
• H01G 11/46 - Metal oxides
• H01G 11/70 - Current collectors characterised by their structure
• H01M 4/04 - Processes of manufacture in general
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/04 - Construction or manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys

Abstract

The present invention relates to a process for preparing a zeolite ZSM-5 presenting a Si/Al molar ratio comprised between 2 and 8, preferably between 3 and 8, comprising the following steps: a) mixing at least one silicon source, at least one aluminum source, at least one organic template and at least one aqueous solvent, in order to obtain a synthesis mixture in solution or gel form; b) ageing the mixture obtained in step a) at a temperature of between 20° C. and 200° C. during at least 30 minutes; and d) crystallizing the resulting mixture during at least 24 hours, wherein a step c) of adding wood lignin or oxidized wood lignin to the mixture is performed after step a) or after step b). It also relates to a zeolite which is obtainable by such a process, and to its use.

IPC Classes  ?

• C01B 39/40 - Type ZSM-5 using at least one organic template directing agent
• B01J 29/40 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 35/61 - Surface area
• B01J 35/63 - Pore volume
• B01J 37/00 - Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
• B01J 37/03 - Precipitation; Co-precipitation
• C07C 1/24 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only oxygen atoms as hetero atoms by elimination of water
• C07C 4/06 - Catalytic processes

Abstract

A system and a method for generating a navigation path for an autonomous system. The method comprises receiving data comprising characteristics of entities, the entities defining an environment in which the autonomous system is configured to operate; receiving first instructions causing the autonomous system to identify a destination in the environment; generating a navigation path comprising waypoints to be followed by the autonomous system to reach the destination, the waypoints being generated based on the characteristics of the entities and defining segmental paths; executing second instructions causing the autonomous system to navigate along the navigation path; and upon navigating from a first waypoint to a second waypoint: accessing updates of the characteristics of the entities located in a vicinity of a corresponding segmental path; generating a sub-path between the first waypoint and the second waypoint based on second information; and navigating along the sub-path to reach the second waypoint.

IPC Classes  ?

• G05D 1/229 - Command input data, e.g. waypoints
• B60W 60/00 - Drive control systems specially adapted for autonomous road vehicles
• G05D 1/656 - Interaction with payloads or external entities

Abstract

A quasi-optical beamformer includes a plurality N> 1 of power feeds (PF), each of the i∈[1; N] power feeds (PF) being configured to emit a respective radio-frequency beam denoted Ri, a radio-frequency transmission line (LT) fed at a first end by the power feeds and comprising at a second end a plurality of network ports (PR) that are configured to collect radio-frequency radiation, the transmission line (LT) comprising a radio-frequency waveguide (GO) that comprises at least two metal plates (PM) that are stacked so as to guide the radio-frequency beams Ri, i∈[1; N] towards the network ports (PR), the transmission line (LT) extending along a central main axis denoted axis x, a first reflector (M1) having a first centre (C1) centred on the axis x and a first effective radius of curvature and being configured to reflect the guided radio-frequency beams Ri, i∈[1; N], a second reflector (M2) having a second effective radius of curvature and being configured to reflect the radio-frequency beams (RFi) reflected by the first reflector so as to direct them towards the network ports so as to form output radio-frequency beams (RSi), the first and second effective radii of curvature and an arrangement of the power feeds (PF) with respect to the first reflector being configured so that: each of the output radio-frequency beams (RSi) is a plane wave, and a transverse amplitude distribution Ai, on the network ports (PR), of each output radio-frequency beam (RSi), is substantially identical.

IPC Classes  ?

• H01Q 19/06 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using refracting or diffracting devices, e.g. lens
• H01Q 9/04 - Resonant antennas
• H01Q 23/00 - Antennas with active circuits or circuit elements integrated within them or attached to them
• H04B 7/06 - Diversity systems; Multi-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the transmitting station

Abstract

FT{ΔTenppee(ω)) (5a, 5b, 5c) from said first Fourier transform

IPC Classes  ?

• G01R 29/08 - Measuring electromagnetic field characteristics
• G01N 25/72 - Investigating presence of flaws

Abstract

22120320620312032062020 aromatic radical, which may be substituted or unsubstituted; for the polymerization of conjugated dienes, in particular the stereospecific polymerization of 1,3-dienes, especially butadiene and isoprene.

IPC Classes  ?

• C08F 4/70 - Iron group metals, platinum group metals, or compounds thereof
• C08F 136/04 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated

Abstract

The subject matter of the present invention is a method for producing such components, the components that can be obtained by this method and the use of these components in the production of a liquid organic electrolyte electrochemical cell.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 50/414 - Synthetic resins, e.g. .thermoplastics or thermosetting resins
• H01M 50/446 - Composite material consisting of a mixture of organic and inorganic materials

Abstract

Quasi-optical beamformer (1) comprising. -a plurality N > 1 of powei feeds (PF), each of the i c [1;N] power feeds (PF) being configured to emit a respective radio-frequency beam denoted Ri, - a radio-frequency transmission line (LT) fed at a first end by the power feeds and comprising at a second end a plurality of network ports (PR) that are configured to collect radio-frequency radiation, the transmission line (LT) comprising a radio-frequency waveguide (GO) that comprises at least two metal plates (PM) that are stacked so as to guide the radio-frequency beams Ri, i c [1; IV] towards the network ports (PR), the lransmission line (LT) extending along a cenlral main axis denoted axis x, - a first reflector (M1) having a first centre (C1) centred on the axis x and a first effective radius of curvature and being configured to reflect the guided radio-frequency beams Roi c [1; N], - a second reflector (M2) having a second effective radius of curvature and being configured to reflect the radio-frequency beams (RF) reflected by the first reflector so as to direct them towards the network ports so as to form output radio-frequency beams (RSi), the first and second effective radii of curvature and an arrangement of the power feeds (PF) with respect to the first reflector being configured so that - each of the output radio-frequency beams (RS,) is a plane wave, and - a transverse amplitude distribution Ai, on the network ports (PR), of each output radio-frequency beam (RS), is substantially identical

IPC Classes  ?

• H01Q 19/17 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces wherein the surfaces are concave the primary radiating source comprising two or more radiating elements
• H01Q 15/14 - Reflecting surfaces; Equivalent structures
• H05K 1/02 - Printed circuits - Details

Abstract

The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis. The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 39/06 - Free radical scavengers or antioxidants
• C07D 209/12 - Radicals substituted by oxygen atoms

Abstract

Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety In of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to new dendrimers with thiophosphoramidate units and derivatives, their preparation method and their use.

IPC Classes  ?

• C07F 9/6593 - 1,3,5-Triaza-2,4,6-triphosphorines
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.

IPC Classes  ?

• C07D 235/04 - Benzimidazoles; Hydrogenated benzimidazoles
• A61P 35/00 - Antineoplastic agents

Abstract

A method for the servo control of an optical device includes a cavity exhibiting resonance around a center frequency ƒc, a laser and a phase modulator, the method being designed to servo-control the cavity to the laser or vice versa and to compensate for an amplitude modulation introduced by the phase modulator, the method comprising, inter alia, the following steps: A. varying a difference δν between the optical frequency of the laser radiation and the center frequency, such that the optical frequency scans the resonance, the difference being controlled by a parameter of an element of the device, and for each difference δνi i. modulating, at a modulation frequency ƒmod, a phase of the laser radiation, through a modulation phase ϕmod, with the phase modulator, ii. injecting the phase-modulated radiation into the cavity, iii. using a photodiode to detect radiation reflected or transmitted by the cavity and generating an electrical signal (St, Sr) representative of the intensity of the detected radiation, iv. demodulating the electrical signal at the modulation frequency ƒmod by synchronously generating a first demodulated signal and a second demodulated signal representative of the demodulated electrical signal, respectively at a first demodulation phase ϕdem,1 and at a second modulation phase ϕdem,2ϕdem,2≈ϕdem,1k, where k∈[0; 2π] is different from the first phase, and by filtering the first and the second signal so as to retain only a DC component of the first demodulated signal Vϵ1, called error signal 1, and of the second demodulated signal Vϵ2, called error signal 2.

IPC Classes  ?

• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/137 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling devices placed within the cavity for stabilising of frequency
• H01S 3/139 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling the mutual position or the reflecting properties of the reflectors of the cavity

Abstract

Disclosed are crystalline hafnium oxide nanoparticles, a method for manufacturing same, and the uses thereof. The invention relates to crystalline hafnium oxide nanoparticles, characterized in that they bear amide molecules and/or at least one amide degradation product chosen from a carboxylic acid, an amine or an amino acid and/or residues of said molecules on their surface.

IPC Classes  ?

• C01G 27/00 - Compounds of hafnium

Abstract

Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.

IPC Classes  ?

• C07D 209/08 - Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• C07D 211/38 - Halogen atoms or nitro radicals
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
• C07D 279/02 - 1,2-Thiazines; Hydrogenated 1,2-thiazines
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 519/04 - Dimeric indole alkaloids, e.g. vincaleucoblastine
• C07D 213/12 - Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
• C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
• C07C 303/40 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups

Abstract

The present application relates to ceramic/polymer hybrid solid electrolytes with improved interfacial strength, comprising a surface-dehydrated pre-treated ceramic.

IPC Classes  ?

• H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
• H01M 10/052 - Li-accumulators
• H01M 6/18 - Cells with non-aqueous electrolyte with solid electrolyte

Abstract

The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti- CD19, anti-EGFR, anti-BCMA…) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/36 - Hydroxylated esters of higher fatty acids
• C08G 18/48 - Polyethers
• C08G 18/66 - Compounds of groups , , or
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes
• C09D 175/08 - Polyurethanes from polyethers
• C08L 75/04 - Polyurethanes

Abstract

The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

A process for preparing a catalyst material, includes: (a) providing a support material having surface hydroxyl (OH) groups, the support material is ceria (CeO2), zirconia (ZrO2) or a combination, and the support material contains between 0.3 and 2.0 mmol OH groups/g of the support material; (b) reacting the support material with at least one of: (b1) a compound containing at least one alkoxy or phenoxy group bound though its oxygen atom to a metal element from Group 5 (V, Nb, Ta) or Group 6 (Cr, Mo, W); (b2) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element from Group 5 or 6; (b3) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element which is copper (Cu); and (c) calcining the product obtained in step (b).

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 23/20 - Vanadium, niobium or tantalum
• B01J 23/22 - Vanadium
• B01J 23/28 - Molybdenum
• B01J 23/30 - Tungsten
• B01J 23/72 - Copper
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 31/22 - Organic complexes
• B01J 37/08 - Heat treatment

Abstract

A catalytic system based on at least one rare-earth metallocene and an organomagnesium reagent as co-catalyst of formula RB—(Mg—RA)m—Mg—RB is provided. According to the formula, RB comprises a benzene nucleus substituted with the magnesium atom. One of the carbon atoms of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl or forms a ring with the carbon atom which is its closest neighbour and which is meta to the magnesium. The other carbon atom of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl. RA is a divalent aliphatic hydrocarbon-based chain, optionally interrupted with one or more oxygen or sulfur atoms or with one or more arylene groups. The m is a number greater than or equal to 1, preferably 1. The catalytic system allows the synthesis of dienic and/or ethylenic telechelic polymers.

IPC Classes  ?

• C08F 4/54 - Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 10/02 - Ethene

Abstract

The invention relates to a cell culture comprising a placental cell and a culture medium consisting of minimal essential nutriments and a low amount of serum. The invention also relates to a method using the cell culture for identifying endocrine disruptor.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

Abstract

A method for recognizing a pattern in an image including a training phase of an oscillatory neuron network, the oscillatory neuron network being adapted to output a pattern when an image is inputted, the oscillatory neuron network being implemented by a circuitry comprising oscillators linked by interconnections including at least one coupling resistance having a coupling resistance value, the oscillators being coupled by a sub-harmonic injection technique and coding the output by their relative phase difference, the coupling resistance values being learnt during the training phase by using Hebbian learning rules, and an operating phase wherein the trained oscillatory neuron network is used to recognize a pattern in an image, at least one of the training phase and the operating phase being computer-implemented.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding

Abstract

The present invention relates to a device for measuring and/or modifying a surface of a sample, including a sample holder, including a first area configured to receive the sample fixedly mounted relative to the first area, a support, a first probe configured to detect a first parameter at a point of the surface and to generate a first measurement signal representative of the first parameter, and a second probe configured to detect a second parameter at a point of the surface, and to generate a second measurement signal representative of the second parameter, the first parameter being different from the second parameter, or one of the first probe and the second probe being configured to modify a third parameter of the surface at the point of the surface.

IPC Classes  ?

• G01Q 60/04 - STM [Scanning Tunnelling Microscopy] combined with AFM [Atomic Force Microscopy]
• G01Q 20/00 - Monitoring the movement or position of the probe
• G01Q 30/14 - Liquid environment
• G01Q 40/00 - Calibration, e.g. of probes
• G01Q 60/16 - Probes, their manufacture or their related instrumentation, e.g. holders
• G01Q 60/38 - Probes, their manufacture or their related instrumentation, e.g. holders

Abstract

An electromagnetic waveguide, such as an optical fibre, including a hollow central core surrounded by a microstructured sheath formed by an assembly of elementary cells, the microstructured sheath also including at least two elementary cells, at least one intermediate element connecting the elementary cells, the intermediate element having a cross-section with an area less than or equal to 50% of the cross-sectional area of each of the cells that it connects, the intermediate element having a refractive index less than or equal to the refractive index of each of the elementary cells that it connects.

IPC Classes  ?

• G02B 6/032 - Optical fibres with cladding with non-solid core or cladding

Abstract

An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.

IPC Classes  ?

• G02B 5/28 - Interference filters
• G02B 1/11 - Anti-reflection coatings
• G02F 1/35 - Non-linear optics

Abstract

The invention relates to a process for treating, with a plasma, a composition comprising at least a first compound and a second compound, characterized in that said process comprises at least: generating, within an enclosure, a non-equilibrium plasma flow from a gas present in said enclosure, and treating the composition contained in said enclosure with said non-equilibrium plasma flow so as to extract at least a portion of said first compound.

IPC Classes  ?

• C22B 4/00 - Electrothermal treatment of ores or metallurgical products for obtaining metals or alloys
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• H05H 1/46 - Generating plasma using applied electromagnetic fields, e.g. high frequency or microwave energy

Abstract

The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 9/50 - Proteinases
• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• B02C 19/00 - Other disintegrating devices or methods

Abstract

The invention relates to an optical substrate (1) having an integrated waveguide (2), at least one antenna (330) being formed in the optical substrate (1), the at least one antenna being formed by a plurality of nanoholes (341, 342, 343), at least one of the nanoholes (341, 342, 343) differing from the other nanoholes (341, 342, 343) by at least one of: its diameter, its spacing of the waveguide (2) in the height direction of the optical substrate (1), and its distance from an adjacent nanohole of the same antenna in the longitudinal direction of the optical substrate (1). The invention also relates to a spectrometer (S) that integrates an optical substrate (1) of this kind.

IPC Classes  ?

• G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• G02B 6/124 - Geodesic lenses or integrated gratings
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means

Abstract

Method for determining an amount of lithium contained in a biological fluid, said method comprising the steps consisting in adding, to a biological fluid sample of known volume, a given volume of a discriminating solution, the effect of which is to obtain a biological fluid solution buffered at a pH of between 6 and 8 and to bring about precipitation of at least a portion of the cations contained in the biological fluid sample except for the lithium Ions. The method further comprises the steps consisting in depositing a given volume of biological fluid solution onto an active layer (2) of an optode (1), said active layer comprising a chemical transducer of which at least one optical property is modified In the presence of lithium ions in the biological fluid solution, in measuring at least one characteristic of at least one light wave emitted or reflected by the active layer of the optode and in determining, from the at least one measured characteristic and from calibration data, an amount of lithium contained in the biological fluid.

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 21/82 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity

Abstract

The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of a BTN3A activating antibody that activates the cytolytic function of Vγ9Vδ2 T cells, and of Venetoclax, which selectively inhibits the Bcl2 receptor, and hypomethylating agents such as Azacytidine, to promote synergistically and specifically Vγ9Vδ2 T cell anticancer activity.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from α-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 263/06 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to a method of directional self-assembly lithography, said method comprising a step of depositing a block copolymer film on a layer (20) neutral with respect the block copolymer, said block copolymer film being for use as a lithography mask, said method being characterized in that it comprises the following steps of: depositing said neutral layer (20) on a surface of a substrate (10), said neutral layer (20) being of the carbon or fluoro-carbon type deposited to a thickness greater than 1.5 times the thickness of the block copolymer film (40), crosslinking said neutral layer, depositing said block copolymer film, comprising at least one silylated block, on said crosslinked neutral layer (30), subjecting the stack to an assembly temperature in order to nanostructure said block copolymer, removing (G1) at least one of the nano-domains (41, 42) from the nanostructured block copolymer film (40), in order to create a pattern intended to be transferred by etching (G2, G3, G4) into the thickness of the substrate (10).

IPC Classes  ?

• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor

Abstract

Deposition of a material such as indium in the form of nitrided thin layers, by evaporation and dual activation using a nitrogen plasma (41) and an electron beam (42).

IPC Classes  ?

• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/26 - Vacuum evaporation by resistance or inductive heating of the source
• C23C 14/24 - Vacuum evaporation
• C23C 14/32 - Vacuum evaporation by evaporation and subsequent ionisation of the vapours
• H01J 37/32 - Gas-filled discharge tubes

Abstract

The invention relates in particular to a cell culture device comprising an insert (1) having an internal cavity (11) delimited by an insert side wall (12) and an insert bottom (10), said internal cavity being able to receive said cell culture in a cell culture fluid so as to create a cell tissue (2). The device comprises a container (3) that removably receives said insert, said side wall (12) having first through-holes (13). The container comprises an internal flue (30) and an opening (33) which allows said insert (1) to be inserted into said flue. The insert bottom comprises second through-holes (14) allowing observation of the cells therethrough, said first and second through-holes being capillary holes able to retain said cell culture fluid in said internal cavity and serving to anchor said cell tissue.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

A method for optimizing a quantum operation to be applied on two quantum objects of a system of quantum objects The present invention relates to a method for optimizing a quantum operation to be applied on at least two quantum objects (12) of a system (10) of quantum objects, the method comprising the determination of an optimized pulse to be generated by at least one controlled laser for implementing the quantum operation on the at least two quantum objects (12) while fulfilling a robustness criterion, the at least two quantum objects (12) having a quantum state depending on the excitation level of the at least two quantum objects, the excitation level being chosen between 01, 10 and 11, 0 defining a de-excited state for a quantum object and 1 defining an excited state for a quantum object, the quantum state having a zero order term and a first order term.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to an optical device for the full-field optical coherence tomography microscopic imaging of at least one sample, the device comprising a lens for observing the sample when in use, the device comprising a specular interface, the device thus being able, when in use, to allow the production of at least one interference between at least one reference wave obtained by the reflection of light emitted by a light source associated with the device from the specular interface, and at least one object wave obtained by the backscattering of the light emitted by the source from the sample, the specular interface being arranged with respect to the lens in such a way that, when in use, the object wave passes through the specular interface on its path between the sample and the source. The invention also relates to the corresponding facility and method.

IPC Classes  ?

• G01B 9/02056 - Passive reduction of errors
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G01B 9/04 - Measuring microscopes
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G02B 21/00 - Microscopes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

One aspect of the invention relates to a method (100) for controlling a mechatronic system, based on a model for predicting the behaviour of the mechatronic system and a cost function ensuring compliance with constraints by the mechatronic system, with a view to following path instructions to a prediction horizon, the method comprising: reformulating (10) the constraints into barrier functions and integrating the barrier functions into the cost function; and for each sampling period of a sequence of sampling periods: obtaining (20) the path instructions and at least one measurement of the mechatronic system in a current state; determining (30) coefficients of a polynomial of order m using a Nelder-Mead method optimizing the cost function based on the predicting model, this determining step receiving as input the path instructions and the at least one measurement of the mechatronic system obtained (20); computing (40) a command through evaluation of the polynomial; and applying (50) the command to the mechatronic system.

IPC Classes  ?

• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
• G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators

Abstract

transOPA1e.g., ex vivoin vivoOPA1OPA1 mutations.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 27/02 - Ophthalmic agents
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0781 - B cells; Progenitors thereof
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 8/06 - Measuring blood flow

Abstract

The present invention relates to a method for identifying potentially relevant markers in cancer diagnosis, prognosis and/or therapy, comprising an analysis approach which is based on the detection of variations in methylation of ribosomal RNAs in a biological sample. The present invention also relates to several applications of this analysis approach for determining the cancer subtype and/or the prognosis of a patient suffering from cancer, for estimating or assessing the benefit of a treatment in such patient, but also for selecting one or more therapeutic drug(s) targeting ribosomes useful for treating cancers.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an isolated double stranded DNA polynucleotide that forms triplex with sequence 5′-GGUGGCAGCAAGAGAAAAAUGAGGAAGAAGCAAAAGCGGAAA-3′ (SEQ ID NO: 1) of the long non-coding RNA ANRIL (Antisense Non-coding RNA in the INK4 Locus). It also relates to a vector comprising the double stranded DNA polynucleotide, and to a pharmaceutical composition comprising the double stranded DNA polynucleotide or the vector. The present invention relates as well to the isolated double stranded DNA polynucleotide for use in the treatment of myocardial infarction, aneurysms, stenosis, myocardial infarction, aneurysms, cancers, eye diseases or type 2 diabetes.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

A system for characterizing a pulse of electromagnetic radiation by time-resolved optical gating, which includes an interference-forming device which is adapted for superimposing four parts of the pulse. The system also includes a matrix image sensor which selectively captures, based on two-photon absorptions, an interference pattern formed by the pulse. The system allows obtaining the pulse shape completely and accurately, and is particularly suitable for characterizing ultrashort pulses. Also, the two-photon absorption can be produced in the matrix image sensor, or replaced by optical frequency doubling which is produced by an SHG crystal plate.

IPC Classes  ?

• G01J 11/00 - Measuring the characteristics of individual optical pulses or of optical pulse trains
• G02B 5/20 - Filters
• H04N 23/12 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from different wavelengths with one sensor only

Abstract

An electrode including a storage film. The storage film includes a layer of a support material including at least one inclusion in which a compound of interest is stored and a wall of permeable sealing material sealing the at least one inclusion. The storage film further includes a porous layer covering, at least in part, the wall of sealing material, at least a portion of a surface of the porous layer constituting an active surface of the electrode.

IPC Classes  ?

• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts

Abstract

The present invention relates to a synergistic combination of an FXR agonist and interferon for the treatment of hepatitis B.

IPC Classes  ?

• A61K 38/21 - Interferons
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/42 - Oxazoles
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) The material has good mechanical properties and does not exhibit a bitter taste.

IPC Classes  ?

• A61K 6/891 - Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61K 6/61 - Cationic, anionic or redox initiators
• A61K 6/62 - Photochemical radical initiators
• A61K 6/77 - Glass

Abstract

A method for monitoring a hadron beam during hadron-therapy treatment of a subject including tumour cells labelled with a radiopharmaceutical product, in which the hadron beam includes a plurality of discrete hadron bursts, the method including the following steps: when a burst impacts on the subject, detecting the prompt gamma generated by the interaction of the hadrons of the burst with the tissues of the subject using a Compton telescope and reconstructing an image of the interaction volume; when no burst impacts on the subject, extracting the position of the tumour cells labelled with the radiopharmaceutical product using the Compton telescope and reconstructing an image of the total volume of the tumour; comparing the image of the interaction volume and the image of the total volume of the tumour so as to locate the measured interaction volume relative to the measured total volume of the tumour.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

222 in a sample, wherein the sample comprises a persistent luminescence nanoparticle.

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• C01G 15/00 - Compounds of gallium, indium, or thallium
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
• G01N 21/76 - Chemiluminescence; Bioluminescence
• G01N 21/70 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light mechanically excited, e.g. triboluminescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to a microfluidic device and to a method for applying at least one hydrodynamic stress of defined intensity and duration to cells in suspension, said cell being in motion in said device, and for characterizing the morphology and the physiological state of these cells during, and optionally after, the application of the hydrodynamic stress.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the said peptides or vectors, CTLs of a subject treated with said peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of said peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/13 - Cyclosporins
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/515 - Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61P 17/00 - Drugs for dermatological disorders

Abstract

123412344, other than hydrogen, comprise from 1 to 30 carbon atoms, optionally substituted with at least one of the groups or substituents.

IPC Classes  ?

• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61Q 19/00 - Preparations for care of the skin
• C10M 105/00 - Lubricating compositions characterised by the base-material being a non-macromolecular organic compound

Abstract

A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

A system to localize a micro-device inside a target body part, including: a micro-device remotely steered and controlled from outside the target body part, a control unit including a memory for storing one ultrasound image of the target body part, one probe being brought in contact with a securing body part of the patient, and at least one tracker connected to the micro-device. The probe and the tracker communicate with ultrasounds, the control unit being thus able to localize, in real time, the tracker within an internal referential defined with regards to the probe, and the control unit displays, on a screen, the ultrasound image and displays, in real time, the localization of the micro-device on the ultrasound image.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets

Abstract

Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types

Abstract

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/04 - Organic compounds
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/60 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

Abstract

The invention relates to a measuring device (10) for measuring physical characteristics of cells. The device (10) comprises: a microfluidic chip (20) provided with a flow channel (22) for allowing cells to flow through; a manipulator (24) configured to apply deformation force to a cell in a continuous flow; and a sensor (26) configured to sense a physical characteristic of the cell. The manipulator (24) and the sensor (26) are configured to define a width (W2) of the flow channel (22) as a gap formed between them. The manipulator (24) is configured to apply the deformation force to the cell by compressing the cell against the sensor (26).

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 15/10 - Investigating individual particles
• G01N 33/487 - Physical analysis of biological material of liquid biological material

Abstract

Positive electrodes based on organic active material, including molecules of thianthrene as the active material, substituted at specific positions. The electrodes have electrochemical properties enabling their use in a battery, in particular a recyclable battery. The electrodes thus replace the electrodes based on mineral salts that are conventionally used in batteries.

IPC Classes  ?

• H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
• H01M 4/04 - Processes of manufacture in general
• H01M 4/139 - Processes of manufacture
• H01M 10/052 - Li-accumulators
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.

IPC Classes  ?

• C14C 3/08 - Chemical tanning by organic agents

Abstract

5242323333.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• C07F 15/02 - Iron compounds
• B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention relates to an elementary particle detector (1) comprising: dynodes (10) capable of converting an elementary particle into an avalanche of electrons; conductive grids (30) through which accelerated electrons are able to pass, each grid being defined by a unique electric potential, each unique electric potential being chosen so that the unique electric potential of said conductive grid (30) is strictly lower than the unique electric potential applied to the conductive grid (30) immediately thereafter in the direction of detection (X); at least one signal sensor (50) able to measure an electric signal (S) produced by the accelerated electrons when they pass through the conductive grids (30); and a control unit (90) configured to determine, on the basis of the electric signal (S), a conversion dynode (18) at which the conversion of the elementary particle has taken place. The invention further relates to an elementary particle detection method.

IPC Classes  ?

• H01J 43/24 - Dynodes having potential gradient along their surfaces
• H01J 43/30 - Circuit arrangements not adapted to a particular application of the tube and not otherwise provided for
• H01J 47/02 - Ionisation chambers

Abstract

A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A signal tracking system including: one fixation element to be secured to a rigid body part of the patient surrounding a target body part, the fixation element further including a mapping element, one tracker element to be secured to the fixation element to track, in real time, the internal tracker, and a control unit including a memory to store an internal referential and one image displaying the target body part and one fixation element. The control unit is designed to define, inside the internal referential, at least one 3D frame position attached to the at least one fixation element, and to precisely locate each point of the target body part, the control unit is further designed to precisely localize, in real time, the internal tracker inside the target body part.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Abstract

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof